Parallel Advisors LLC Buys 1,369 Shares of IDEAYA Biosciences, Inc. $IDYA

Parallel Advisors LLC increased its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 72.4% during the 2nd quarter, Holdings Channel.com reports. The firm owned 3,260 shares of the company’s stock after acquiring an additional 1,369 shares during the quarter. Parallel Advisors LLC’s holdings in IDEAYA Biosciences were worth $69,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of IDYA. CWM LLC grew its stake in shares of IDEAYA Biosciences by 325.7% during the first quarter. CWM LLC now owns 2,371 shares of the company’s stock valued at $39,000 after purchasing an additional 1,814 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of IDEAYA Biosciences by 180.2% during the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock valued at $39,000 after purchasing an additional 1,546 shares during the last quarter. Signaturefd LLC grew its stake in shares of IDEAYA Biosciences by 374.8% during the first quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock valued at $47,000 after purchasing an additional 2,271 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in shares of IDEAYA Biosciences by 46.4% during the first quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock valued at $109,000 after purchasing an additional 2,112 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of IDEAYA Biosciences by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 7,483 shares of the company’s stock valued at $123,000 after purchasing an additional 627 shares during the last quarter. 98.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Citizens Jmp assumed coverage on shares of IDEAYA Biosciences in a research note on Thursday, September 4th. They issued a “mkt outperform” rating and a $41.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 9th. Citigroup reaffirmed a “buy” rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 9th. Stephens reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, September 9th. Finally, The Goldman Sachs Group raised shares of IDEAYA Biosciences to a “hold” rating and set a $25.00 price objective on the stock in a research note on Thursday, July 10th. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.36.

IDEAYA Biosciences Stock Up 0.1%

Shares of NASDAQ IDYA opened at $25.69 on Friday. The company’s fifty day moving average is $24.54 and its 200-day moving average is $21.13. The stock has a market cap of $2.25 billion, a price-to-earnings ratio of -6.78 and a beta of 0.12. IDEAYA Biosciences, Inc. has a twelve month low of $13.45 and a twelve month high of $32.67.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.03). The firm had revenue of $6.00 million for the quarter, compared to the consensus estimate of $3.48 million. The firm’s quarterly revenue was up NaN% on a year-over-year basis. During the same quarter last year, the company posted ($0.68) earnings per share. On average, research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.